BAUSCH HEALTH COMPANIES INC.

ISIN: CA0717341071 WKN: 071734107

Overview


2024/07/11 22:0	0:01	
Price 7.55 USD		
Difference	0	3.14% (0.23)

General attributes	
ISIN	CA0717341071
Symbol	ВНС
Exchange	NYSE
Currency	USD
Sector	Other
Security type	Stock
Market cap (m)	2,547 EUR
Benchmark	S&P/TSX 60 INDEX

Market data	
Bid (Bid size)	7.35 USD (100)
Ask (Ask size)	7.59 USD (200)
Open	7.40 USD
High	7.57 USD
Low	7.35 USD
Close (prev. day)	7.32 USD
VWAP	7.366699 USD
Volume (pcs)	9,062,515
Trading volume	66,784,310.48
Number of trades	12,847
Last size	-

Futures and Options	
Related Futures	15
Related Options	-





Information about previous performance does not guarantee future performance. **Source:** FactSet

Recent research

on sector			
Date		Headline	Download
2024/06/21	80 28 87 188	Global Equity Ratings	
2024/06/14	84 (2) 21 (8)	Global Equity Ratings	
2024/05/29	8. 28 87 188	Global Equity Ratings	
2024/04/26	84 (2) 21 (8)	Global Equity Ratings	
2024/04/03	8. 28 87 18	Global Equity Ratings	




Details

2024/07/11 22:00:01			
Price			
7.55 USD			
Difference	O	3.14% (0.23)	

General attributes	
ISIN	CA0717341071
Symbol	ВНС
Exchange	NYSE
Currency	USD
Sector	Other
Security type	Stock
Market cap (m)	2,547 EUR
Benchmark	S&P/TSX 60 INDEX

Market data	
Bid (Bid size)	7.35 USD (100)
Ask (Ask size)	7.59 USD (200)
Open	7.40 USD
High	7.57 USD
Low	7.35 USD
Close (prev. day)	7.32 USD
VWAP	7.366699 USD
Volume (pcs)	9,062,515
Trading volume	66,784,310.48
Number of trades	12,847
Last size	_

Performance and Risk					
	6m	1Y	3Y		
Perf (%)	-9.35%	-11.48%	-71.79%		
Perf (abs.)	-0.72	-0.90	-17.70		
Beta	1.12	1.19	1.76		
Volatility	39.27	40.40	71.51		



Information about previous performance does not guarantee future performance. $\textbf{Source:} \ \ \textbf{FactSet}$

Price data	
Ø price 5 days Ø volume 5 days (pcs.)	7.32 USD (3,776,858)
Ø price 30 days Ø volume 30 days (pcs.)	6.67 USD (2,420,060)
Ø price 100 days Ø volume 100 days (pcs.)	8.06 USD (2,967,930)
Ø price 250 days Ø volume 250 days (pcs.)	8.02 USD (2,694,797)
YTD High date	11.46 USD (2024/04/03)
YTD Low date	6.05 USD (2024/06/14)
52 Weeks High date	11.46 USD (2024/04/03)
52 Weeks Low date	6.05 USD (2024/06/14)
52 Weeks High date	11.46 USD (2024/04/03)

All listings for BAUSCH HEALTH COMPANIES INC.					
Exchange 🖨	Date	Time	Price	Trading volume (mio.)	Number of trades
Tradegate	2024/07/ 11	22:02	6.953 EUR	0.00	1
Toronto Stock Exchange	2024/07/ 11	22:00	10.29 CAD	3.43	1,850
Stuttgart	2024/07/ 11	21:54	6.906 EUR	0.01	15
SIX Swiss Exchange	2019/06/ 28	17:35	24.11 CHF	0.00	1
NYSE	2024/07/	22:00	7.55 USD	66.78	12,847



	11		
Munich	2024/07/ 11	08:01 6.675 EUR 0.00	2
Frankfurt	2024/07/ 11	13:09 6.686 EUR 0.00	3
Duesseldorf	2024/07/ 11	08:10 6.668 EUR 0.00	3
Berlin	2024/07/ 11	14:40 6.806 EUR 0.01	2



Company profile

Company Logo

BAUSCH Health

Contact Details

BAUSCH HEALTH COS. INC.

_ _

2150 St. Elzéar Boulevard West - H7L 4A8 Laval

Telefon: +1-514-744-6792

Fax: + E-mail: -

PDF Downloads

Company report: BAUSCH HEALTH COMPANIES INC.

Company Profile

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Wellibers of Management Board	
Thomas Appio	Chairman of Managing Board
Tage Ramakrishna	Member of Executive Committee
Cees Heiman	Member of Executive Committee
Fernando Zarate	Member of Executive Committee
Graham Jackson	Member of Executive Committee
Jeff Hartness	Member of Executive Committee
Kathleen Fitzpatrick	Member of Executive Committee
Mirza Dautbegovic	Member of Executive Committee

Member of Executive

Member of Executive

Committee

Committee

Seana Carson

Tom Vadaketh

Members of Management Roard

æ,

Board of directors	
John Paulson	Chairman of Supervisory Board
Amy Wechsler	Member of Supervisory Board
Richard Mulligan	Member of Supervisory Board
Brett Icahn	Member of Supervisory Board
Christian Garcia	Member of Supervisory Board
Frank Lee	Member of Supervisory Board
Robert Power	Member of Supervisory Board
Sarah Kavanagh	Member of Supervisory Board
Steven Miller	Member of Supervisory Board

